Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBT (2023 - 2025)

Rallybio (RLYB) has disclosed EBT for 3 consecutive years, with -$5.9 million as the latest value for Q4 2025.

  • Quarterly EBT rose 44.87% to -$5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.1 million through Dec 2025, up 85.41% year-over-year, with the annual reading at -$8.1 million for FY2025, 85.41% up from the prior year.
  • EBT hit -$5.9 million in Q4 2025 for Rallybio, down from $16.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $16.0 million in Q3 2025 to a low of -$19.6 million in Q4 2023.
  • Historically, EBT has averaged -$11.3 million across 3 years, with a median of -$13.3 million in 2024.
  • Biggest five-year swings in EBT: fell 9.48% in 2024 and later surged 247.9% in 2025.
  • Year by year, EBT stood at -$19.6 million in 2023, then soared by 45.93% to -$10.6 million in 2024, then soared by 44.87% to -$5.9 million in 2025.
  • Business Quant data shows EBT for RLYB at -$5.9 million in Q4 2025, $16.0 million in Q3 2025, and -$9.4 million in Q2 2025.